The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
March 12th 2025
The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.
Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNP
February 7th 2025The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]
FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment
Published: February 4th 2025 | Updated: February 6th 2025SPN-830 is a wearable subcutaneous infusion device designed to deliver continuous treatment throughout the waking day, ensuring more consistent control of OFF time.
Implementing MRI-Guided Focused Ultrasound: Challenges and Opportunities
January 28th 2025Neurologists Steven Lewis, MD, and Behrang Saminejad, MD, of Lehigh Valley Health Network, provided commentary on the ways to successfully implement focused ultrasound as a treatment for essential tremor and Parkinson disease.
Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease
January 15th 2025The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.
Syn-One Test Displays Significant Clinical Utility for the Diagnosis of Synucleinopathies
December 22nd 2024Since the Syn-One Test only needs a small punch skin biopsy that can be collected in an office setting, the clinical utility can be enhanced to offer more geographically convenient access for patients earlier in the disease.
Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes
December 20th 2024Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.
Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
December 3rd 2024To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.
StrivePD: Revolutionizing Parkinson Disease Care Through Data and Personalization
November 23rd 2024Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders, gave comments on the innovation behind the StrivePD app and how it can revolutionize personalized treatment management for patients with Parkinson disease.
Coupling Eye Movements and Postural Sway Significantly Enhances Stability in Parkinson Disease
November 22nd 2024Findings from a recently published study suggest patients with Parkinson disease can reduce postural sway as efficiently as neurologically healthy patients when performing horizontal saccades.
VQ-101 Show Promise in Interim Phase 1 Data for GBA-Parkinson Disease Treatment
November 16th 2024According to the company, VQ-101 is the first small molecule to show over 75% activation of the lysosomal enzyme GCase in humans, with phase 1 results in healthy volunteers indicating tolerability and exposure levels that support once-daily dosing.
GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings
November 14th 2024Initial findings showed significant improvements from baseline in the disease-specific, patient-reported quality of life scores in both the high and low dose AAV-GAD groups, with no significant change in the sham group at 26 weeks.
Using Data Collection to Improve Parkinson Disease Treatment Personalization: Amanda Hare, DNP
November 14th 2024The doctor of nursing practice specialized in movement disorders discussed specific data the StrivePD app captures and how it can enhance quality of life for patients with Parkinson disease. [WATCH TIME: 3 minutes]
Therapeutic Advantages of StrivePD for Parkinson Disease Management: Amanda Hare, DNP
November 13th 2024The doctor of nursing practice specialized in movement disorders provided clinical insight on how the StrivePD application empowers patients with Parkinson disease to track symptoms, medication, and daily activities using an iPhone and Apple Watch. [WATCH TIME: 3 minutes]